News

Long-term results for the GRIPHON trial are in. According to a presentation made at the 35th Annual International Society for Heart and Lung Transplantation (ISHLT) Meeting & Scientific Sessions, selexipag (otherwise known as Uptravi® from Actelion) effectively treats patients with pulmonary arterial…

Serodus ASA recently announced that the company has filed a provisional patent application with the United Kingdom patent office for its experimental SER100 therapy, which will begin development for treatment of Pulmonary Hypertension. “We are pleased to introduce a new indication for one of our drug candidates. SER100 will now also be…

In a new study entitled “Salidroside attenuates chronic hypoxia-induced pulmonary hypertension via adenosine A2a receptor related mitochondria-dependent apoptosis pathway,” the authors report on the beneficial effects of salidroside in treating hypoxia-induced pulmonary arterial hypertension by decreasing arterial remodeling and promoting pulmonary arterial smooth muscle cells apoptosis. The study was…

In a study titled “Increased prevalence of EPAS1 variant in cattle with high-altitude pulmonary hypertension,” researchers discovered two genetic variants responsible for brisket disease in cattle that may provide clues to human conditions associated with pulmonary hypertension. The study was published in the journal Nature Communications. High-altitude…

Results from a recent study published in the journal Respirology showed that an early decline in 6-minute walk test (6MWT) distance predicts deterioration of disease condition in patients with pulmonary arterial hypertension (PAH). The findings could provide new insights into effectively diagnosing and treating the disease using…

The Pulmonary Hypertension Association (PHA) is initiating a new social network, called myPHA, which was designed particularly for patients who suffer from pulmonary hypertension (PH). The resource was created to resemble a one-stop-shop virtual home, in which patients can interact with each other, as well…

Recent work in preclinical models suggests that signaling via the pro-angiogenic and pro-inflammatory cytokine, CXCL12 (SDF-1), plays an important pathogenic role in pulmonary hypertension (PH). Now a research team found that elevated concentrations of circulating CXCL12α predicts poorer survival in patients with Pulmonary Arterial Hypertension (PAH) and…

Irving, Texas-based Reata Pharmaceuticals, Inc. has been granted orphan drug designation from the U.S. Food and Drug Administration (FDA) for its pulmonary arterial hypertension (PAH) treatment. The FDA’s Office of Orphan Products Development (OOPD) awarded the designation to bardoxolone methyl due to its novel…

April has been named the month for highlighting the importance of organ donation for those living with pulmonary hypertension (PH). The Pulmonary Hypertension Association (PHA) is celebrating Donate Life Month to encourage people to become organ donors and be aware of the need for early screening, diagnosis, and treatment of the disease. The PHA depends on…

The Pulmonary Hypertension Association (PHA), for the 12th consecutive year, has received a 4-star rating from Charity Navigator — the premier evaluator of charities in the United States. This premium designation indicates that PHA adheres to sound fiscal management, good governance, transparency, commitment to accountability and other best practices,…

In a new study entitled “Relationship between pulmonary hypertension, peripheral vascular calcification, and major cardiovascular events in dialysis patients,” the authors identify a relation between pulmonary hypertension and increase risk for cardiovascular problems in dialysis patients. The study was published in the journal for…

The Montreal Heart Institute is currently recruiting patients for a Phase-IIc clinical trial that is evaluating the safety of PulmoBind in participants with pulmonary hypertension and its potential to detect abnormal pulmonary circulation associated within pulmonary hypertension. (ClinicalTrials.gov Identifier: NCT02216279). Pulmonary hypertension is a condition that causes gradual loss…